Talk:Valproic acid: Difference between revisions
imported>Robert Badgett (New page: {{subpages}}) |
imported>David E. Volk (variants and sources) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
== Acid and sodium salt == | |||
First, I'd like to find a better source on the indications for use of valproic acid versus valproate sodium. My clinical experience, however, is much more with the use in mood disorders and neurogenic pain than for convulsive disorders, and when I've asked some of the physicians prescribing why the salt and not the acid, I've never gotten an especially clear answer. | |||
Second, raises a general question for pharmacology articles. What range of relatively small molecular variants should be under the same article? Some variants seem simply for manufacturing or marketing, while others actually do affect bioavailability. | |||
In turn, this leads to the question of when it is best to address, as a family, therapeutic agents where there may be both prodrug and active metabolite preparations. This may be more of a Forum question, but I thought I would start here. [[User:Howard C. Berkowitz|Howard C. Berkowitz]] 12:08, 29 June 2008 (CDT) | |||
== variants and sources == | |||
The variants don't really matter, because the acid is going become deprotonated to the anion as will the sodium salt, so effectively they are the same thing (valproate anion) once ingested. | |||
For sources, check the external links for DrugBank, the FDA site, etc. You will find complete information within those pages. [[User:David E. Volk|David E. Volk]] 12:16, 29 June 2008 (CDT) | |||
Latest revision as of 11:16, 29 June 2008
Acid and sodium salt
First, I'd like to find a better source on the indications for use of valproic acid versus valproate sodium. My clinical experience, however, is much more with the use in mood disorders and neurogenic pain than for convulsive disorders, and when I've asked some of the physicians prescribing why the salt and not the acid, I've never gotten an especially clear answer.
Second, raises a general question for pharmacology articles. What range of relatively small molecular variants should be under the same article? Some variants seem simply for manufacturing or marketing, while others actually do affect bioavailability.
In turn, this leads to the question of when it is best to address, as a family, therapeutic agents where there may be both prodrug and active metabolite preparations. This may be more of a Forum question, but I thought I would start here. Howard C. Berkowitz 12:08, 29 June 2008 (CDT)
variants and sources
The variants don't really matter, because the acid is going become deprotonated to the anion as will the sodium salt, so effectively they are the same thing (valproate anion) once ingested.
For sources, check the external links for DrugBank, the FDA site, etc. You will find complete information within those pages. David E. Volk 12:16, 29 June 2008 (CDT)